Tissue Repair
Klow
KLOW blend; GHK-Cu + BPC-157 + TB-500 + KPV; Glow + KPV; healing+anti-inflammatory blend
Four-component regenerative blend (Glow + KPV anti-inflammatory)
This Klow entry draws on 5 cited sources published 2005 to 2018. The evidence available is graded Anecdotal on this site's scale. Dosing is reported as described in the literature rather than as guidance. Sources checked .
At a glance
- Class
- Four-component regenerative blend (Glow + KPV anti-inflammatory)
- Drug class
- Tissue Repair
- Structure
- Vendor canonical: GHK-Cu + BPC-157 + TB-500 + KPV in fixed ratios (Peptide Sciences 80 mg vial: 50/10/10/10 mg). Compounded variants vary; confirm per-component dosing before use
- Route
- SC injection
- Half-life
- Composite: hours to days per component (TB-500 longest)
- Evidence tier
- Anecdotal
- Availability
- Compounding Restricted
Mechanism of action
Composite formulation layering matrikine signalling, cytoprotection, actin regulation, and NF-kB suppression: GHK-Cu (copper-peptide matrikine activating ~4,000 wound-healing / collagen-elastin genes), BPC-157 (angiogenesis via VEGFR2 + epithelial / tendon repair), TB-500 (actin sequestration + stem-cell mobilisation + anti-fibrotic), KPV (alpha-MSH-derived tripeptide inhibiting NF-kB at mucosal epithelium). Klow is essentially the Glow blend plus KPV for an inflammation-suppression arm.
Reported areas of research
Inflammatory tissue / mucosal repair; injury and post-surgical recovery; skin regeneration; gut-barrier support when inflammation is part of the picture; broader repair spectrum than Glow alone (adds the KPV anti-inflammatory arm)
Items above describe areas studied in published peptide literature, not approved indications. Most peptides catalogued here are not FDA-approved for human use.
Dosage protocols reported in literature
Typical SC protocols deliver ~250 mcg of each component daily (per-component basis from a combined-mg vial) for 4-8 week loading cycles. Confirm vial composition with vendor before computing per-component dose
Reported research dosing only. This is not a clinical recommendation. Consult a qualified clinician before any human use.
Known concerns and limitations
No human-trial data on the combined formulation; each component carries its own risk profile (TB-500 WADA-banned, theoretical pro-proliferative concerns; copper accumulation at chronic GHK-Cu doses); injection-site reactions; meaningful batch-to-batch composition variability across compounders
Compared with
Klow has published head-to-head comparisons with 10 compounds that share its pharmacological class: mechanism, half-life, reported research dosing, evidence tier and regulatory status side by side.
Frequently asked questions
What dosing is reported for Klow in research literature?
Published peptide research reports the following dosing approach for Klow: Typical SC protocols deliver ~250 mcg of each component daily (per-component basis from a combined-mg vial) for 4-8 week loading cycles. Confirm vial composition with vendor before computing per-component dose. This is a research reference, not a clinical recommendation.
How is Klow administered in research?
Klow is administered via the following routes in published studies: SC injection.
What is the reported half-life of Klow?
The reported half-life of Klow is Composite: hours to days per component (TB-500 longest).
Is Klow FDA-approved?
No. Klow is not an FDA-approved drug. PeptideHelper.org catalog status: Compounding Restricted.
What level of evidence supports Klow?
The current evidence base for Klow is best characterised as: Anecdotal. See the methodology page for the full evidence-tier rubric.
What side effects are reported for Klow?
Known concerns reported in the literature for Klow include: No human-trial data on the combined formulation; each component carries its own risk profile (TB-500 WADA-banned, theoretical pro-proliferative concerns; copper accumulation at chronic GHK-Cu doses); injection-site reactions; meaningful batch-to-batch composition variability across compounders. Always consult a qualified clinician before any human use.
Is there anyone who should not use Klow?
No formal contraindications are established for Klow, because it is not an FDA-approved medicine and no approved label exists to define them. That is an absence of regulatory review rather than evidence of safety. Reported concerns from the literature are: No human-trial data on the combined formulation; each component carries its own risk profile (TB-500 WADA-banned, theoretical pro-proliferative concerns; copper accumulation at chronic GHK-Cu doses); injection-site reactions; meaningful batch-to-batch composition variability across compounders. Always consult a qualified clinician before any human use.
How does Klow work?
The mechanism of action reported for Klow in the literature: Composite formulation layering matrikine signalling, cytoprotection, actin regulation, and NF-kB suppression: GHK-Cu (copper-peptide matrikine activating ~4,000 wound-healing / collagen-elastin genes), BPC-157 (angiogenesis via VEGFR2 + epithelial / tendon repair), TB-500 (actin sequestration + stem-cell mobilisation + anti-fibrotic), KPV (alpha-MSH-derived tripeptide inhibiting NF-kB at mucosal epithelium). Klow is essentially the Glow blend plus KPV for an inflammation-suppression arm..
What is Klow studied for?
Klow has been studied in the published literature for: Inflammatory tissue / mucosal repair; injury and post-surgical recovery; skin regeneration; gut-barrier support when inflammation is part of the picture; broader repair spectrum than Glow alone (adds the KPV anti-inflammatory arm). These are areas of research, not established clinical uses unless the compound is FDA-approved for them.
What is Klow?
Klow is classified as: Four-component regenerative blend (Glow + KPV anti-inflammatory). Also known as: KLOW blend; GHK-Cu + BPC-157 + TB-500 + KPV; Glow + KPV; healing+anti-inflammatory blend.
Drug class
- Tissue-repair peptides, see all peptides tagged Tissue-repair.
- Anti-inflammatory peptides, see all peptides tagged Anti-inflammatory.
- Matrikine peptides, see all peptides tagged Matrikine.
- Copper-peptide peptides, see all peptides tagged Copper-peptide.
Research focus area
All peptides studied for Tissue Repair, ranked by evidence tier and regulatory status.
Primary sources
- Pickart L et al. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int 2015. PMID 26236731
- Sikiric P et al. Stable gastric pentadecapeptide BPC 157 — review of pharmacology. Curr Pharm Des 2018. PMID 29804522
- Goldstein AL et al. Thymosin beta4 — actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med 2005. PMID 16099219
- Dalmasso G et al. KPV: a novel anti-inflammatory peptide derived from alpha-MSH inhibits epithelial pro-inflammatory pathways. Gastroenterology 2008. PMID 18054553
- Note: Klow is a vendor-marketed multi-peptide blend with no published human trials of the combination; component ratios vary by compounder. Cited papers describe each component separately.
Open the full interactive PeptideHelper.org reference to compare peptides side-by-side, evaluate stacks, and explore the catalog.
Spot an error or a missing source on this page? Suggest a correction. Corrections are logged and surfaced in the next review.
Loading interactive view…